Major Depressive Disorder Clinical Trial
Official title:
Translational Biomarkers of Fast Acting Therapies in Major Depression
Verified date | August 2019 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The drug Ketamine, available in medical practice since the late 1960s, is currently used for inducing general anesthesia or sedation during medical procedures. When given slowly as an injection into a vein, ketamine is shown to produce a very rapid effect on depression and to improve depressive symptoms within hours to days. By studying patients who receive a ketamine IV infusion, as an add-on treatment for depression, investigators may start to understand how changes in the brain or in gene function relate to getting better over a very short period of time. In this study, the investigators will enroll 60 patients currently ill with major depression selected to receive IV ketamine therapy under medical supervision. To study neurobiological changes relating to symptom improvement, the investigators will use advanced brain scans to measure brain structure, chemistry and function. Blood samples will measure changes in gene regulation and immune system response. Although some people have a rapid antidepressant response to ketamine, others do not respond. Also, antidepressant effects after ketamine usually wear off within days to weeks. We will determine if up to four doses of ketamine delivered two to three times a week may prolong antidepressant response to ketamine therapy. To determine the durability of ketamine treatment for depression, patients will be monitored by phone and via electronic devices twice a week for up to five weeks and will return for a final assessment when their symptoms return. For this trial, brain and blood sample measurements will occur before and after a patient receives their first ketamine infusion. Patients who do not remit after an initial dose of ketamine, will receive up to three additional ketamine treatments. Mood will be measured 24-hours after each subsequent ketamine infusion and brain and blood measurements be repeated at the time of remission or after the fourth ketamine infusion if remission does not occur. Patients will return for a final brain scan and blood sample when their depressive symptoms return or at five weeks if they continue remission. Investigators will able to see how changes brain measurements, gene regulation and immune response relate to improvements and relapse of depressive symptoms with ketamine IV therapy. The ketamine infusion sessions will occur at a special research unit (CTRC) at UCLA.
Status | Completed |
Enrollment | 60 |
Est. completion date | August 2019 |
Est. primary completion date | August 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility |
Inclusion Criteria: - Age between 18 to 64 years, inclusive - Diagnosis: DSM-IV TR criteria for non-psychotic major depression - Hamilton Depression Rating Scale-17 item = 18 or Montgomery Asberg Depression Scale = 20 - A history of at least one previous major depressive episode prior to the current episode - Recurrent Depression - in the current episode, have not responded to at least 2 adequate antidepressant trials (using Antidepressant Treatment History Form criteria) - Have been continuously depressed for between 6-12 months - Receiving approved monoaminergic antidepressant therapy - No changes in antidepressant medication(s) in the past one (1) month - Voluntary patient receiving ketamine - Capacity to provide informed consent - Have no contraindications to an adjunctive trial of ketamine infusion - Be under the current care of a treating Psychiatrist - If outpatient, a responsible driver available for transportation to and from scanning sessions - Live locally, within travelling distance to UCLA - Be available to participate for a 5-week research follow-up Exclusion Criteria: - Younger than 18 or older than 64 - Serious and imminent suicidal or homicidal risk (active suicidal ideations with or without a plan, HAM-D score = 3 on item 3) - Mental retardation or other developmental disorder - Diagnosis of dementia of any type - History of current substance abuse or dependence - Psychotic reactions to medications, alcohol or illicit substances in the past - Current or past history of psychosis, schizophrenia, bipolar disorder, delusional disorder or other psychotic disorder - Treatment with medications with NMDA and NMDAR action - Contraindication to ketamine - Depression related to serious medical illness (i.e., mood disorder due to general medical condition) - History of neurological disorder or other physical disorder (i.e. significant head injury) that could affect brain functioning - Serious or unstable medical or neurological condition(s) that in the opinion of the treating physician or PI renders ketamine unsafe to administer - Any condition that would contraindicate scanning (metal implants, claustrophobia or a breathing or movement disorder) - Pregnancy (as confirmed by positive urine pregnancy test) or planning on becoming pregnant - Non-English speaking (due to scales administered) - Live outside of the Los Angeles area |
Country | Name | City | State |
---|---|---|---|
United States | Geffen School of Medicine, UCLA | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the Hamilton Depression Rating Scale measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions | Change in mood ratings from the Hamilton Depression Rating Scale | up to 2 weeks | |
Primary | Change in the Hamilton Depression Rating Scale measured between the last ketamine infusion treatment and 5 week follow-up | Change in mood ratings from the Hamilton Depression Rating Scale | 5 weeks | |
Secondary | Change in gene expression measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions | Change in gene expression measured from peripheral blood | up to 2 weeks | |
Secondary | Change in gene expression measured between the last ketamine infusion treatment and 5 week follow-up | Change in gene expression measured from peripheral blood | 5 weeks | |
Secondary | Change in non-invasive Magnetic Resonance Imaging measures of structural connectivity measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions | Change in MRI measures of structural connectivity | up to 2 weeks | |
Secondary | Change in non-invasive Magnetic Resonance Imaging measures of structural connectivity measured between the last ketamine infusion treatment and at 5 weeks | Change in MRI measures of structural connectivity | 5 weeks | |
Secondary | Change in non-invasive Magnetic Resonance Imaging measures of functional connectivity measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions | Change in MRI measures of functional connectivity | up to 2 weeks | |
Secondary | Change in non-invasive Magnetic Resonance Imaging measures of functional connectivity measured between the last ketamine infusion treatment and at 5 weeks | Change in MRI measures of functional connectivity | 5 weeks | |
Secondary | Change in non-invasive Magnetic Resonance Imaging measures of neurochemistry measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions | Change in MRI measures of brain metabolite levels | up to 2 weeks | |
Secondary | Change in non-invasive Magnetic Resonance Imaging measures of neurochemistry measured between the last ketamine infusion treatment and at 5 weeks | Change in MRI measures of brain metabolite levels | 5 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |